Amygdalin extracts from almonds and apricots as anticancer agents in human oral carcinoma - an in vitro investigation
Main Article Content
Abstract
Background: In recent years, the application of complementary medicine to treat an array of conditions, including cancer, has surged in prominence. Investigations have indicated that amygdalin, a naturally occurring chemical derived from plants, has anticarcinogenic impacts on several types of cancer. Method: The current work used human oral cancer cell lines, namely the oral cell line SCC-9, to evaluate the anticarcinogenic impact of amygdalin extracted from almonds and apricots. A meticulous extraction method from fresh apricots and almonds was employed to accomplish this. After that, SCC-9 cells were treated with these extracts at different doses ranging from 0 to 100 μg/ml. Acridine orange/ethidium bromide staining, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test, and neutral red uptake assay (NRU) were used to assess the effectiveness of amygdalin. Conclusion: The findings demonstrated the anti-cancer qualities of amygdalin, which is found in almonds and apricots. This demonstrates that it is a therapeutic strategy which can be helpful in treating oral cancer.
Received date: 11-12-2024
Accepted date: 01-02-2025
Published date 15-03-2025
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Cheong SC, Vatanasapt P, Yi-Hsin Y, Zain RB, Kerr AR, Johnson NW. Oral Cancer in South East Asia. Transl Res Oral Oncol. 2017; 2.
Bosetti C, Carioli G, Santucci C, Bertuccio P, Gallus S, Garavello W, et al. Global Trends in Oral and Pharyngeal Cancer Incidence and Mortality. Int J Cancer. 2020; 147: 1040–1049.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209–249.
Peres MA, Macpherson LMD, Weyant RJ, Daly B, Venturelli R, Mathur MR, et al. Oral Diseases: A Global Public Health Challenge. The Lancet. 2019; 394: 249–260.
Borse V, Konwar AN, Buragohain P. Oral Cancer Diagnosis and Perspectives in India. Sens Int. 2020; 1: 100046.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and Neck Squamous Cell Carcinoma. Nat Rev Dis Primers. 2020; 6: 92.
Jiang X, Wu J, Wang J, Huang R. Tobacco and Oral Squamous Cell Carcinoma: A Review of Carcinogenic Pathways. Tob Induc Dis. 2019; 17: 29.
Senevirathna K, Jayasinghe YA, Jayawickrama SM, Amarasinghe H, Jayasinghe RD. Oral Cancer Disease among the Poor: A Sri Lankan Context. Oral. 2023; 3: 420–436.
Irani S. New Insights into Oral Cancer—Risk Factors and Prevention: A Review of Literature. Int J Prev Med. 2020; 11: 202.
Brook I. Late Side Effects of Radiation Treatment for Head and Neck Cancer. Radiat Oncol J. 2020; 38: 84–92.
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020; 7: 193.
Elumalai K, Srinivasan S, Shanmugam A. Review of the Efficacy of Nanoparticle-Based Drug Delivery Systems for Cancer Treatment. Biomed Technol. 2024; 5: 109–122.
Xu L, Sanders L, Li K, Chow JCL. Chatbot for Health Care and Oncology Applications Using Artificial Intelligence and Machine Learning: Systematic Review. JMIR Cancer. 2021; 7: e27850.
Krejbich P, Birringer M. The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review. Antioxidants. 2022; 11: 2149.
Rizeq B, Gupta I, Ilesanmi J, AlSafran M, Rahman MM, Ouhtit A. The Power of Phytochemicals Combination in Cancer Chemoprevention. J Cancer. 2020; 11: 4521–4533,
Jaszczak-Wilke E, Polkowska Ż, Koprowski M, Owsianik K, Mitchell AE, Bałczewski P. Amygdalin: Toxicity, Anticancer Activity and Analytical Procedures for Its Determination in Plant Seeds. Molecules. 2021; 26: 2253.
El-Ela FIA, Gamal A, Elbanna HA, ElBanna AH, Salem HF, Tulbah AS. In Vitro and In Vivo Evaluation of the Effectiveness and Safety of Amygdalin as a Cancer Therapy. Pharmaceuticals. 2022; 15: 1306.
Barakat H., Aljutaily T, Almujaydil MS, Algheshairy RM, Alhomaid RM, Almutairi AS, et al. Amygdalin: A Review on Its Characteristics, Antioxidant Potential, Gastrointestinal Microbiota Intervention, Anticancer Therapeutic and Mechanisms, Toxicity, and Encapsulation. Biomolecules. 2022; 12: 1514.
Spanoudaki M, Stoumpou S, Papadopoulou SK, Karafyllaki D, Solovos E, Papadopoulos K, et al. Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery. Int J Mol Sci. 2023; 24: 14270.
Makarević J, Rutz J, Juengel E, Kaulfuss S, Reiter M, Tsaur I. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2. PLoS One. 2014; 9(8): e105590.
Mosayyebi B, Mohammadi L, Kalantary-Charvadeh A, Rahmati M. Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines. Curr Mol Pharmacol. 2021; 14(4): 667-675.
Mani J, Neuschäfer J, Resch C, Rutz J, Maxeiner S, Roos F. Amygdalin Modulates Prostate Cancer Cell Adhesion and Migration In Vitro. Nutr Cancer. 2020; 72(3): 528-537.
Sireesha D, Reddy B, Reginald B, Samatha M, Kamal F. Effect of Amygdalin on Oral Cancer Cell Line: An in Vitro Study. J Oral Maxillofac Pathol. 2019; 23: 104–107.
Arshi A, Hosseini SM, Hosseini FSK, Amiri ZY, Hosseini FS, Sheikholia Lavasani M, et al. The Anti-Cancer Effect of Amygdalin on Human Cancer Cell Lines. Mol Biol Rep. 2019; 46: 2059–2066.
Caroline ML. Muthukumar RS. A H H, N N. Anticancer Effect of Plectranthus Amboinicus and Glycyrrhiza Glabra on Oral Cancer Cell Line: An Invitro Experimental Study. Asian Pac J Cancer Prev 2023; 24: 881–887.
Mamdouh AM, Khodeer DM, Tantawy MA, Moustafa YM. In-Vitro and in-Vivo Investigation of Amygdalin, Metformin, and Combination of Both against Doxorubicin on Hepatocellular Carcinoma. Life Sci. 2021; 285: 119961.
Hosny S, Sahyon H, Youssef M, Negm A. Prunus Armeniaca L. Seed Extract and Its Amygdalin Containing Fraction Induced Mitochondrial-Mediated Apoptosis and Autophagy in Liver Carcinogenesis. Anticancer Agents Med Chem. 2021; 21: 621–629,
Askar MA, El-Sayyad GS, Guida MS, Khalifa E, Shabana ES, Abdelrahman IY. Amygdalin-Folic Acid-Nanoparticles Inhibit the Proliferation of Breast Cancer and Enhance the Effect of Radiotherapy through the Modulation of Tumor-Promoting Factors/ Immunosuppressive Modulators in Vitro. BMC Complement Med Ther. 2023; 23: 162,
Cassiem W, de Kock M. The Anti-Proliferative Effect of Apricot and Peach Kernel Extracts on Human Colon Cancer Cells in Vitro. BMC Complement Altern Med. 2019; 19: 32.
Ramadan A, Kamel G, Awad NE, Shokry AA, Fayed HM. The Pharmacological Effect of Apricot Seeds Extracts and Amygdalin in Experimentally Induced Liver Damage and Hepatocellular Carcinoma. J Herbmed Pharmacol. 2020; 9: 400–407,
Kitic D, Miladinovic B, Randjelovic M, Szopa A, Sharifi-Rad J, Calina D, Seidel V, et al. Anticancer Potential and Other Pharmacological Properties of Prunus Armeniaca L.: An Updated Overview. Plants. 2022; 11: 1885.
Moradipoodeh B, Jamalan M, Zeinali M, Fereidoonnezhad M, Mohammadzadeh G. In Vitro and in Silico Anticancer Activity of Amygdalin on the SK-BR-3 Human Breast Cancer Cell Line. Mol Biol Rep. 2019; 46: 6361–6370,
Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020; 21: 1960,
Sireesha D, Reddy BS, Reginald BA, Samatha M, Kamal F. Effect of amygdalin on oral cancer cell line: An in vitro study. J Oal Maxillofac Pathol. 2019; 23(1): 104-107.
Meléndez C, Muñoz P, Segura-Aguilar J. DT-Diaphorase Prevents Aminochrome-Induced Lysosome Dysfunction in SH-SY5Y Cells. Neurotox Res. 2019; 35(1): 255-259.
Brolih S, Parks SK, Vial V, Durivault J, Mostosi L, Pouysségur J. et al. AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity. BMC Cancer. 2018; 18(1):249.
Asano S, Taniguchi Y, Yamawaki Y, Gao J, Harada K, Takeuchi H, et al. Suppression of cell migration by phospholipase C-related catalytically inactive protein-dependent modulation of PI3K signalling. Sci Rep. 2017; 7(1): 5408.
Liczbiński P, Bukowska B. Molecular Mechanism of Amygdalin Action in Vitro: Review of the Latest Research. Immunopharmacol Immunotoxicol. 2018; 40: 212–218,
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/β-Catenin Signaling in Cancers and Targeted Therapies. Signal Transduct Target Ther. 2021; 6: 307,
Huang J.-Y, Lin Y.-C, Chen H.-M, Lin J.-T, Kao S.-H. Adenine Combined with Cisplatin Promotes Anticancer Activity against Hepatocellular Cancer Cells through AMPK-Mediated P53/P21 and P38 MAPK Cascades. Pharmaceuticals. 2022;15: 795